Scholarlink

Background <p>Non-small cell lung cancer (NSCLC) is one of the primary contributors to global cancer mortality. Elevated expression of centrosomal protein 55 (CEP55) is frequently observed in NSCLC and is closely linked to tumorigenesis and disease progression. However, the prognostic value of CEP55 in NSCLC has not been fully established. The current meta-analysis assessed how increased CEP55 expression may influence prognosis in patients diagnosed with NSCLC.</p> Methods <p>Eligible studies were retrieved via a systematic search across major biomedical databases. Additionally, validation cohorts were retrieved from the Gene Expression Omnibus (GEO) database. To quantify the prognostic relevance of CEP55, hazard ratios (HRs) and 95% confidence intervals (CIs) were synthesized from eligible studies. The Newcastle-Ottawa Scale was leveraged to assess the methodological quality of the included studies. This review was registered with PROSPERO (CRD420251006676).</p> Results <p>A total of 18 independent study cohorts (6 literature-derived and 12 database-derived) involving 4,829 patients were included. The meta-analysis revealed that elevated CEP55 expression was significantly associated with poorer overall survival (OS) in NSCLC patients [HR = 1.22, 95% CI: 1.13–1.32]. Subgroup analysis by histological subtype showed that CEP55 serves as an independent predictor of poor OS in lung adenocarcinoma (LUAD) [HR = 1.28, 95% CI: 1.20–1.37], whereas its prognostic utility in lung squamous cell carcinoma (LUSC) was not statistically significant [HR = 0.98, 95% CI: 0.90–1.06]. Multivariate analysis further confirmed CEP55 as an independent risk factor for LUAD, with its prognostic impact being particularly evident in early-stage disease characteristics—including Stage I, limited tumor infiltration (T1–T2), and the absence of distant metastasis (M0)—as well as in patients with negative surgical margins or those who had not received chemotherapy.</p> Conclusion <p>CEP55 may act as a potential indicator for predicting disease progression and survival outcomes in NSCLC, particularly in LUAD. Further investigation into the underlying mechanisms of CEP55 is necessary.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic significance of CEP55 expression in non-small cell lung cancer: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月18日

查看全文
  • Jiaxu Wang,
  • Yusong Cao,
  • Jianchun Duan

摘要

Background

Non-small cell lung cancer (NSCLC) is one of the primary contributors to global cancer mortality. Elevated expression of centrosomal protein 55 (CEP55) is frequently observed in NSCLC and is closely linked to tumorigenesis and disease progression. However, the prognostic value of CEP55 in NSCLC has not been fully established. The current meta-analysis assessed how increased CEP55 expression may influence prognosis in patients diagnosed with NSCLC.

Methods

Eligible studies were retrieved via a systematic search across major biomedical databases. Additionally, validation cohorts were retrieved from the Gene Expression Omnibus (GEO) database. To quantify the prognostic relevance of CEP55, hazard ratios (HRs) and 95% confidence intervals (CIs) were synthesized from eligible studies. The Newcastle-Ottawa Scale was leveraged to assess the methodological quality of the included studies. This review was registered with PROSPERO (CRD420251006676).

Results

A total of 18 independent study cohorts (6 literature-derived and 12 database-derived) involving 4,829 patients were included. The meta-analysis revealed that elevated CEP55 expression was significantly associated with poorer overall survival (OS) in NSCLC patients [HR = 1.22, 95% CI: 1.13–1.32]. Subgroup analysis by histological subtype showed that CEP55 serves as an independent predictor of poor OS in lung adenocarcinoma (LUAD) [HR = 1.28, 95% CI: 1.20–1.37], whereas its prognostic utility in lung squamous cell carcinoma (LUSC) was not statistically significant [HR = 0.98, 95% CI: 0.90–1.06]. Multivariate analysis further confirmed CEP55 as an independent risk factor for LUAD, with its prognostic impact being particularly evident in early-stage disease characteristics—including Stage I, limited tumor infiltration (T1–T2), and the absence of distant metastasis (M0)—as well as in patients with negative surgical margins or those who had not received chemotherapy.

Conclusion

CEP55 may act as a potential indicator for predicting disease progression and survival outcomes in NSCLC, particularly in LUAD. Further investigation into the underlying mechanisms of CEP55 is necessary.